Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2018 · 10-Q
Revenue$3.84M$3.84M+45.4% vs Q1 2017 Net Income-$3.51M-$3.51MN/M vs Q1 2017 EPS, diluted—
Gross Profit$1,762,000+79.6% Operating Income-$3,383,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow-$4,634,000N/M Free Cash Flowderived-$4,791,000N/M Margins · derivedGross margin45.9%+8.8 pt vs Q1 2017
Operating margin-88.2%+44.8 pt vs Q1 2017
Net margin-91.5%+5.9 pt vs Q1 2017
ended Jun 30, 2017 · filed Aug 8, 2017 · 39 d after period end